Colchicine safe for patients with comorbidities Arthritis biologics may cut Alzheimer’s risk Lowering urate cuts cardiovascular deaths Hyperuricemia deserves more aggressive treatment, researcher says Osteoporosis: There’s an app for that New Canadian guidelines offer a choice of risk assessment tools Uloric: first new option for gout in more than 40 years Takeda Canada will soon be introducing Uloric (febuxostat 80 mg) tablets, the first new drug to be marketed for gout in more than four decades. Men and Women's Health 2010: Osteoporosis New developments in therapy, vitamin D requirements, bisphosphonate safety and risk assessment. Arthritis care benefits from team approach Leading Ontario clinic spreading its model of chronic disease management across Canada Actemra: anaphylaxis risk Hoffmann-La Roche and Health Canada warn about potential risk of fatal anaphylaxis with Actemra (tocilizumab). Rheumatoid arthritis redefined Canadian doctor played a major role in international effort to overhaul RA criteria New drugs on the way for gout Experimental compounds control pain and reduce serum uric acid levels First Previous 17 18 19 20 Next Last
